Helping You Build Wealth With Honest Research
Since 1996. Read On...

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Revealed
India's Third Giant Leap

This Could be One of the Biggest Opportunities for Investors




Important: We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
By submitting your email address, you also sign up for Profit Hunter, a daily newsletter from Equitymaster
covering exciting investing ideas and opportunities in India.

AD

Downward streak in Asia continues
Mon, 21 Nov 09:30 am

Asian stock markets continued their downward streak this week as well with stock markets in Taiwan (down 2.3%), Hong Kong (down 1.9%) and Indonesia (down 1.6%) leading the losses. The Indian stock market have also opened the day on a weak note. Stocks in the Oil and gas, metal and auto space are leading the losses.

The BSE-Sensex is trading lower by 142 points (0.9%), while the NSE-Nifty is down by around 43 points (0.9%). Mid cap and small cap stocks are also trading in the red, with the BSE Mid Cap and BSE Small Cap indices down by 0.6% and 0.1% respectively. The rupee is trading at 51.51 to the US dollar.

Auto stocks have opened the day on a weak note with Tata Motors and Bajaj Auto leading the losses. India's leading passenger carmaker Maruti Suzuki is planning to introduce more models with the environment-friendly CNG (compressed natural gas) option. The company currently has five models in CNG options- Alto, WagonR, Estilo, Eeco and SX4. Maruti's Chairman Mr R C Bhargava has asserted that the automobile industry needs the government's support in order to make vehicles with eco-friendly fuel options a success. There is a requirement to make CNG available across the country and adequate CNG needs to be allocated for automotive use. Besides planning to introduce more models with CNG options, the carmaker is also working to offer hybrid and electric vehicles at affordable rates.

Pharma stocks have opened the day on a mixed note with Biocon, Ranbaxy Laboratories and Orchid Chemicals facing selling pressure. However, Dishman Pharma, Aurobindo Pharma and Indoco Remedies are trading in the green. Dr Reddy's laboratories (DRL) said that the workers from its Srikakulam manufacturing facility in Andhra Pradesh have called off a 3-month old strike. Nearly 400 contract workers were on strike demanding wage hikes and employment status as permanent workers. The deadlock between the management and the workers had remained for the past 3 months. The company was finally successful in negotiating with the contract workers and this was facilitated by the district administration officials. As a part of the understanding, the contract workers will be engaged as per the shift requirement. The Labour department of Andhra Pradesh confirmed that an understanding was reached between the workers and management. As a part of the settlement, nearly 180 contract workers will be employed as permanent workers.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "Downward streak in Asia continues". Click here!

  
ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited).

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407

Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.